Evidence map›Paper›PMID 12939642›Full record

ArticleGene therapy2003

Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.

D Nagorsen, M Panelli, M E Dudley, S E Finkelstein, S A Rosenberg, F M Marincola

Open access · greenAbstract read
In one paragraph

Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. HLA typing demands for peptide-based anti-cancer vaccine.Cancer immunology, immunotherapy : CII · 2008
    Article
  8. Review
  9. Article
  10. Understanding the response to immunotherapy in humans.Springer seminars in immunopathology · 2005
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

D NagorsenImmunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
M Panelli
M E Dudley
S E Finkelstein
S A Rosenberg
F M Marincola
National Institutes of Health Clinical Center · USNational Cancer Institute · USNational Institutes of Health · US

Funding

THE IMMUNOTHERAPY OF ANIMAL AND HUMAN CANCERZ01SC003811 · SC · CLINICAL SCIENCES · PI ROSENBERG, STEVEN A · 1996 to 2007
$3.2M
Immunogenetics of Vaccine TherapyZ01CL002115 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2003 to 2005
–
Intramural NIH HHS Z01 SC003811
6 · The paper itself

Abstract

Recombinant expression vectors represent a powerful way to deliver whole antigens (Ags) for immunization. Sustained Ag expression in vector-infected dendritic cells (DC) combines Ag-specific stimulation with powerful costimulation and, simultaneously, through 'self-selection' of ad hoc epitopes broadens the scope of immunization beyond restrictions posed by individual patients' human leukocyte antigen (HLA) phenotype. In this study, therefore, we evaluated the efficiency of a recombinant vaccinia virus encoding the gp100/PMel17 melanoma Ag (rVV-gp100) to infect immature (iDC) or mature dendritic cells (mDC) derived from circulating mononuclear cells and the effect of infection on their status of maturation. In addition, we tested the ability of rVV-gp100-infected iDC and mDC to present the HLA-A*0201-associated gp100:209-217 epitope (g209). Irrespective of status of maturation, rVV-gp100 infection induced gp100 expression while only partially reversing the expression of some maturation markers. However, endogenous presentation of the wild-type g209 epitope was inefficient. The low efficiency was epitope-specific since infection of DC with rVV encoding a gp100 construct containing the modified gp100:209-217 (210M) (g209-2M) epitope characterized by high binding affinity for HLA-A*0201 restored efficient Ag presentation. Presentation of an HLA-class II-associated epitope and cytokine release by DC was not altered by rVV infection. Thus, Ag expression driven by rVV may be an efficient strategy for whole Ag delivery. However, since the effectiveness of Ag processing and presentation is subject to stringent HLA/epitope pairing, and for other yet undefined rules, the assumption that whole Ag delivery may circumvent HLA restriction is incorrect and recombinant expression vectors encoding well-characterized polyepitopic constructs may prove more effective.

Indexed as

Antigen PresentationCancer VaccinesCD4-Positive T-LymphocytesCell LineClone CellsDendritic CellsEpitopesFlow CytometryGenetic TherapyGenetic Vectorsgp100 Melanoma AntigenHLA-A2 AntigenHLA-A AntigensHumansInterferon-gammaMelanomaCancer VaccinesEpitopesg209-2M melanoma peptidegp100 Melanoma AntigenHLA-A*02:01 antigenHLA-A2 AntigenHLA-A AntigensInterferon-gammaMembrane GlycoproteinsNeoplasm ProteinsPeptidesPMEL protein, humanReceptors, Antigen, T-Cell

Identifiers

PMID12939642
PMCPMC2275329
OpenAlexW2053212927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.